ViroPharma Incorporated
730 Stockton Drive
Exton
Pennsylvania
19341
United States
Tel: 610-458-7300
Fax: 610-458-7380
Website: http://www.viropharma.com/
Email: questions@viropharma.com
About ViroPharma Incorporated
ViroPharma Incorporated is a global biotechnology company dedicated to developing and commercializing products that help address dangerous, potentially life-threatening conditions such as hereditary angioedema (HAE), seizures in children and adolescents, and adrenal insufficiency. ViroPharma is headquartered in Exton, PA and has operations throughout Europe.ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs. ViroPharma has gained commercial approval for three important therapeutics in the United States or Europe, with several others in clinical development. For example, our product Cinryze (R) (C1 Esterase Inhibitor (human)) is indicated in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In Europe, it is indicated for prophylaxis against HAE attacks, pre-procedure prophylaxis, and acute treatment of attacks of HAE in children and adolescents with HAE.
HAE is a rare inherited disorder which is characterized by painful swelling that can appear in various parts of the body. It most commonly affects the hands, feet, face, abdomen, urogenital tract, and upper respiratory tract. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attack, life-threatening. If left untreated, HAE can result in a mortality rate as high as 40%, primarily due to upper airway obstruction or suffocation in undiagnosed patients.
ViroPharma is engaged in life-cycle management work with Cinryze on additional indications, formulations, and territories. In addition, our preclinical and clinical pipeline includes non-toxigenic C. difficile (NTCD), targeting prevention of recurrence of disease following therapy for acute C. difficile infection (CDI), a phase 1 compound targeting a rare disease called Friedreich's ataxia, several clinical and investigator initiated studies of C1 esterase inhibitor in diseases mediated by the complement cascade, and our Phase 2 agent called maribavir, targeting transplant-associated cytomegalovirus (CMV) infection.
Through the success ViroPharma’s products and our management team’s savvy business model, the company’s is well positioned financially to continue to add new products that will provide hope to physicians treating patients with unmet medical needs.
ViroPharma is an equal opportunity employer and promotes diversity throughout its organization. A strong foundation of shared values among the people of ViroPharma, brought together with a clear and common purpose, has contributed to the culture of ViroPharma. The company is seeking individuals with the skills and passion for results to join the ViroPharma team as part of the catalyst to future success. In addition to a rewarding work environment emphasizing teamwork, commitment and communication, ViroPharma provides competitive salaries, medical/dental benefits, a 401(k) plan and stock options.
Please visit ViroPharma’s Online Recruitment Center to complete a profile and apply.
284 articles about ViroPharma Incorporated
-
Niche Drugmaker ViroPharma Incorporated Attracts Takeover Interest -Sources
6/18/2013
-
ViroPharma Incorporated Receives Orphan Drug Designation for Maribavir in Europe
6/11/2013
-
ViroPharma Incorporated to Participate in Several June Healthcare Investor Conferences
6/3/2013
-
Subgroup Analyses of Pivotal and Open Label Prevention Trials Showed Effectiveness of ViroPharma Incorporated's Cinryze® (C1 Esterase Inhibitor [Human]) in Prevention of Angioedema Attacks in Patients with Hereditary Angioedema (HAE) Poorly Controlle
5/29/2013
-
ViroPharma Incorporated to Participate In Two May Healthcare Investor Conferences
5/10/2013
-
ViroPharma Incorporated Announces First Quarter 2013 Financial Results
5/1/2013
-
ViroPharma Incorporated to Release 2013 First Quarter Financial Results on May 1, 2013
4/25/2013
-
ViroPharma Incorporated Release: Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) in a Phase 2 Study Resulted in High Rates of Colonization and Statistically Significant Reductions in Recurrence of C. difficile Infection
4/22/2013
-
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
2/27/2013
-
ViroPharma Incorporated to Release 2012 Fourth Quarter and Full Year Financial Results on February 27, 2013
2/22/2013
-
ViroPharma Incorporated to Participate in Two Upcoming Healthcare Investor Conferences
2/11/2013
-
ViroPharma Incorporated Release: Sub-Group Analysis of Data From Pediatric Patients With Hereditary Angioedema Published in the Journal of Pediatrics
1/16/2013
-
ViroPharma Incorporated Suit Against FDA Over Generic Vancocin Tossed
1/10/2013
-
ViroPharma Incorporated Provides 2013 Outlook
1/7/2013
-
ViroPharma Incorporated and Halozyme Therapeutics, Inc. Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze® (C1 Esterase Inhibitor [Human]) With Hyaluronidase (rHuPH20)
12/19/2012
-
ViroPharma Incorporated Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
12/12/2012
-
ViroPharma Incorporated to Participate in Two December Healthcare Investor Conferences
11/30/2012
-
ViroPharma Incorporated's Cinryze® (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema
11/13/2012
-
ViroPharma Incorporated to Participate in Two November Healthcare Investor Conferences
11/9/2012
-
ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
10/25/2012